![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/14/2881263/7281/en/XOMA-to-Present-at-H-C-Wainwright-2nd-Annual-Bioconnect-Investor-Conference-at-NASDAQ.html
https://www.globenewswire.com/news-release/2024/05/09/2878664/7281/en/XOMA-Reports-First-Quarter-2024-Financial-Results-and-Highlights-Recent-Activities.html
https://www.globenewswire.com/news-release/2024/04/25/2869527/7281/en/XOMA-Earns-9-Million-Milestone-as-FDA-Grants-Accelerated-Approval-to-Day-One-s-OJEMDATM-tovorafenib-for-Relapsed-or-Refractory-BRAF-altered-Pediatric-Low-Grade-Glioma-pLGG.html
https://www.globenewswire.com//news-release/2024/02/16/2830729/7281/en/XOMA-Enters-into-Agreement-to-Acquire-Kinnate-Biopharma-for-Between-2-3352-and-2-5879-in-Cash-Per-Share-Plus-a-Contingent-Value-Right.html
https://www.globenewswire.com//news-release/2024/01/18/2811533/7281/en/XOMA-Expands-its-Commercial-Royalty-and-Milestone-Portfolio-with-DSUVIA-Acquisition.html
https://www.globenewswire.com//news-release/2024/01/11/2808325/7281/en/FDA-Acceptance-of-Zevra-s-Arimoclomol-NDA-Filing-for-Niemann-Pick-Disease-Type-C-NPC-Results-in-XOMA-Making-a-1-Million-Milestone-Payment-to-LadRx.html
https://www.globenewswire.com//news-release/2024/01/02/2802594/7281/en/XOMA-Announces-Stock-Repurchase-Program-of-up-to-50-Million.html
https://www.globenewswire.com//news-release/2023/09/25/2748527/7281/en/XOMA-Declares-Quarterly-Preferred-Stock-Dividends.html
https://www.globenewswire.com//news-release/2023/09/06/2738255/7281/en/XOMA-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html